NASDAQ:BIIB - Biogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have increased by 6.7% and is now trading at $314.06. View which stocks have been mosted impacted by Coronavirus.

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, April 22nd 2020. View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings data on Thursday, January, 30th. The biotechnology company reported $8.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.02 by $0.32. The biotechnology company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.51 billion. Biogen had a return on equity of 46.51% and a net margin of 40.96%. The firm's revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $6.99 EPS. View Biogen's earnings history.

Biogen announced that its board has approved a share buyback plan on Monday, December 23rd 2019, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

Biogen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $31.50-33.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $31.98. The company issued revenue guidance of ~$14.0-14.3 billion, compared to the consensus revenue estimate of $13.85 billion.

30 analysts have issued 1 year target prices for Biogen's shares. Their forecasts range from $231.00 to $410.00. On average, they expect Biogen's stock price to reach $325.17 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price. View analysts' price targets for Biogen.

Media headlines about BIIB stock have been trending very positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biogen earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutBiogen.

Biogen saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 3,560,900 shares, an increase of 13.4% from the February 27th total of 3,140,000 shares. Based on an average trading volume of 1,835,900 shares, the days-to-cover ratio is presently 1.9 days. Approximately 2.1% of the shares of the company are short sold. View Biogen's Current Options Chain.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Celgene (CELG), Walt Disney (DIS), Micron Technology (MU) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $314.06.

Biogen has a market capitalization of $54.67 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe. View additional information about Biogen.

The official website for Biogen is http://www.biogen.com/.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]